ENLIVEN THERAPEUTICS, INC. (ELVN) Free cash flow 2019–2025
ENLIVEN THERAPEUTICS, INC. (ELVN) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$70.5MFY2025 · since FY2019: -$22.0M → -$70.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$70.5M | +3.8% |
| FY2024 | -$73.2M | -19.2% |
| FY2023 | -$61.4M | -87.9% |
| FY2022 | -$32.7M | +30.1% |
| FY2021 | -$46.8M | -25.0% |
| FY2020 | -$37.4M | -69.9% |
| FY2019 | -$22.0M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice